John Murphy, M.D., M.P.H., D.P.H.
Abstract
Background: Saliva has emerged as a central biological medium in SARS-CoV-2 infection, functioning simultaneously as a diagnostic fluid, a viral reservoir, and a reflection of systemic and mucosal immune perturbation. COVID-19 has revealed previously underappreciated roles of salivary glands in viral replication, host transmission dynamics, and post-acute sequelae.
Methods: This narrative synthesis integrates peer-reviewed evidence from virology, oral biology, and clinical COVID-19 research examining salivary viral load, glandular infection, ACE2/TMPRSS2 expression in oral tissues, salivary immunoglobulin responses, and post-acute salivary dysfunction.
Findings: SARS-CoV-2 infects salivary gland epithelium via ACE2 and TMPRSS2-mediated entry, leading to detectable viral RNA in saliva early in infection. Saliva demonstrates viral loads comparable to or exceeding nasopharyngeal swabs in early disease. Infection induces dysregulation of salivary secretion, alterations in mucin composition, and immune activation characterized by salivary IgA and IgG responses. Post-acute COVID-19 is associated with persistent xerostomia, dysgeusia, and altered salivary proteomics.
Interpretation: Saliva is not merely a passive diagnostic medium but a biologically active compartment reflecting direct viral tropism and host immune response. Salivary gland involvement may contribute to transmission efficiency and long-term oral sequelae.
1. Introduction
COVID-19 fundamentally altered the understanding of respiratory viral pathophysiology by establishing that SARS-CoV-2 is not restricted to the lower and upper respiratory tract but also actively infects oral tissues, including salivary glands.
Early in the pandemic, saliva was rapidly recognized as a viable diagnostic fluid due to consistent detection of viral RNA. Subsequent mechanistic studies demonstrated that this was not merely contamination from the nasopharynx, but rather a reflection of active replication within salivary gland epithelial cells.
Expression analyses confirmed abundant ACE2 and TMPRSS2 in salivary glands, particularly ductal and acinar cells, providing a direct molecular entry route for viral infection.¹²
2. Molecular Entry and Viral Tropism in Salivary Tissue
SARS-CoV-2 entry into host cells depends primarily on:
- ACE2 receptor binding
- TMPRSS2-mediated spike protein priming
Multiple studies have demonstrated:
- High ACE2 expression in tongue epithelium, salivary glands, and oral mucosa³
- Co-localization of TMPRSS2 in salivary ductal and acinar cells⁴
This establishes salivary glands as primary viral replication reservoirs rather than passive conduits.
A systematic review of oral tissues confirmed that ACE2 is widely expressed in salivary gland epithelial compartments, supporting susceptibility to infection.⁵
3. Salivary Viral Load Dynamics in COVID-19
Clinical studies consistently demonstrate that:
- Saliva viral load is highest in early infection
- It correlates with symptom severity
- It may exceed nasopharyngeal viral concentrations in early disease stages
A large clinical cohort analysis showed that saliva viral load correlates strongly with systemic inflammatory markers and disease severity trajectories.⁶
Saliva viral burden has been identified as a predictor of clinical outcome, with higher loads associated with worse disease progression and mortality risk.⁷
4. Salivary Gland Infection and Functional Disruption
Histopathological and transcriptomic studies demonstrate:
- Infection of ductal and acinar epithelial cells
- Cellular stress responses and apoptosis pathways activation
- Altered secretory protein expression profiles
This leads to clinically observed symptoms including:
- Xerostomia (dry mouth)
- Dysgeusia (taste disturbance)
- Altered saliva viscosity and mucin composition
These findings suggest that COVID-19-associated oral symptoms are not purely neurological but partially glandular in origin.
5. Salivary Immune Response to SARS-CoV-2
Saliva contains a complex mucosal immune environment dominated by IgA.
COVID-19 induces:
- Elevated salivary IgA targeting spike protein
- Presence of neutralizing antibodies in oral secretions
- Local cytokine expression consistent with mucosal immune activation
These responses suggest saliva plays a dual role:
- Viral transmission medium
- First-line mucosal immune barrier
6. Saliva as a Diagnostic and Prognostic Fluid
Saliva-based diagnostics have demonstrated:
- Comparable sensitivity to nasopharyngeal swabs in RT-PCR testing⁸
- Feasibility for rapid antigen and molecular detection
- Utility in longitudinal monitoring of viral shedding
Importantly, saliva sampling is non-invasive, scalable, and reduces healthcare worker exposure.
7. Post-Acute COVID-19 Salivary Dysfunction
Emerging evidence indicates long-term salivary alterations in post-COVID conditions:
- Persistent xerostomia
- Altered salivary proteome composition
- Possible dysregulation of autonomic control of salivary secretion
These findings align with broader post-viral syndromes affecting mucosal surfaces.
8. Discussion
The involvement of saliva in COVID-19 is mechanistically grounded in:
- Direct viral tropism for salivary gland epithelium
- High ACE2 expression in oral tissues
- Robust local immune response in saliva
This reframes saliva not as a secondary diagnostic medium but as a primary site of viral-host interaction.
The implications extend to:
- Transmission biology (aerosolization via saliva)
- Diagnostic strategy (non-invasive surveillance)
- Long-term oral sequelae of infection
. Salivary Proteomics and SARS-CoV-2–Induced Molecular Remodeling
Beyond viral detection, saliva in COVID-19 exhibits profound proteomic remodeling, reflecting both direct epithelial infection and systemic inflammatory spillover.
Mass spectrometry-based salivary proteomic studies have identified:
- Upregulation of inflammatory proteins (e.g., S100A8/A9, calprotectin)
- Acute-phase reactants (e.g., C-reactive protein fragments)
- Downregulation of mucosal barrier proteins (e.g., mucins MUC5B, MUC7)
- Altered salivary amylase isoforms associated with autonomic stress responses
These changes suggest that SARS-CoV-2 infection induces a shift from homeostatic lubrication and antimicrobial function toward an inflammatory secretome profile.
Importantly, proteomic signatures persist beyond acute infection in subsets of patients with post-acute sequelae, suggesting durable glandular reprogramming rather than transient inflammation.
10. Salivaomics and Multi-Omic Integration in COVID-19
The emerging field of salivaomics integrates proteomic, transcriptomic, metabolomic, and microbiomic data from saliva to characterize disease states.
10.1 Transcriptomic alterations
Salivary RNA profiles in COVID-19 patients demonstrate:
- Increased interferon-stimulated gene expression (ISG15, OAS1, MX1)
- Elevated epithelial cell stress transcripts
- Viral RNA fragments consistent with active replication in oral tissues
10.2 Metabolomic shifts
COVID-19 saliva metabolomic studies reveal:
- Altered amino acid metabolism (notably tryptophan and arginine pathways)
- Increased oxidative stress metabolites
- Reduced short-chain fatty acid derivatives associated with oral microbiome balance
These findings indicate a metabolic signature of mucosal immune activation and oxidative stress.
10.3 Microbiome disruption
SARS-CoV-2 infection is associated with:
- Reduced oral microbial diversity
- Expansion of opportunistic pathogens (e.g., Streptococcus anginosus group)
- Dysbiosis linked to inflammatory cytokine elevation in saliva
This supports a model in which COVID-19 induces a tri-layer disruption: epithelial, immune, and microbial homeostasis.
11. Salivary Cytokine Networks in COVID-19
Saliva contains a dynamic cytokine milieu reflecting both local and systemic inflammation.
Key findings include elevated:
- IL-6 (central mediator of systemic inflammation)
- IL-1β (epithelial and macrophage activation)
- TNF-α (vascular permeability and tissue injury signaling)
- IFN-γ (antiviral immune response coordination)
Notably, salivary IL-6 levels correlate with:
- Disease severity
- Oxygen requirement
- Systemic CRP levels
This positions saliva as a non-invasive surrogate for systemic cytokine burden.
A proposed mechanism suggests that salivary glands act as both:
- Local cytokine producers
- Filtration sites for systemic inflammatory mediators
12. Dysgeusia and Salivary-Gustatory Axis Dysfunction
One of the most clinically distinctive symptoms of COVID-19 is taste disturbance (dysgeusia or ageusia).
Mechanistically, this is multifactorial:
12.1 Direct epithelial injury
- Infection of taste bud-supporting cells expressing ACE2
- Disruption of taste receptor turnover cycles
12.2 Salivary composition alteration
- Reduced solubilization of tastants due to altered mucin content
- Changes in electrolyte balance affecting taste receptor activation
12.3 Neural-immune interaction
- Cytokine-mediated modulation of gustatory nerve signaling
- Inflammatory suppression of TRPM5-dependent taste pathways
Together, these mechanisms support a triadic model of dysgeusia involving epithelial, salivary, and neural components.
13. Autonomic Dysfunction and Salivary Hypofunction in COVID-19
Salivary secretion is tightly regulated by the autonomic nervous system. COVID-19 appears to disrupt this regulation through:
- Vagal nerve dysfunction (post-viral autonomic imbalance)
- Sympathetic overactivation during systemic inflammation
- Possible neurotropic effects of SARS-CoV-2 on autonomic nuclei
Clinical consequences include:
- Xerostomia (dry mouth)
- Thickened saliva consistency
- Reduced unstimulated salivary flow rates
These findings align with broader post-COVID autonomic syndromes, including POTS-like presentations in some patients.
14. Post-Acute COVID-19 and Chronic Salivary Gland Dysfunction
A growing subset of patients experience persistent oral symptoms months after infection.
14.1 Clinical manifestations
- Chronic dry mouth
- Persistent dysgeusia
- Oral burning sensation (burning mouth–like syndrome)
- Intermittent salivary gland swelling
14.2 Proposed mechanisms
(a) Viral persistence hypothesis
Low-level viral RNA or protein persistence in salivary epithelium may sustain immune activation.
(b) Immune-mediated glandular injury
Autoimmune-like responses targeting salivary epithelial antigens following viral priming.
(c) Fibrotic remodeling
Chronic inflammation leading to:
- Acinar cell loss
- Ductal remodeling
- Reduced secretory capacity
Histologic parallels are being explored with post-viral sialadenitis models.
15. Saliva as a Reservoir for Transmission and Public Health Implications
Saliva is a key vector in SARS-CoV-2 transmission through:
- Speech-generated droplets
- Aerosolization during breathing and coughing
- Contamination of surfaces via oral secretions
High salivary viral loads in early infection strongly correlate with transmissibility, supporting the concept that saliva is not only diagnostic but epidemiologically central to spread dynamics.
This has implications for:
- Mask efficacy (droplet interception)
- Speech-based transmission modeling
- Non-invasive mass testing strategies
16. Integrative Pathophysiological Model
Based on current evidence, COVID-19-related salivary dysfunction can be conceptualized as a multilayered system failure:
- Viral Entry Layer
- ACE2/TMPRSS2-mediated infection of salivary epithelium
- Secretory Disruption Layer
- Acinar dysfunction and mucin alteration
- Immune Activation Layer
- Local cytokine and IgA response dysregulation
- Neuroautonomic Layer
- Dysregulation of parasympathetic salivary control
- Microbiome Layer
- Dysbiosis and opportunistic bacterial expansion
This framework integrates molecular, cellular, and systems-level pathology into a unified model of salivary involvement in COVID-19.
17. Interim Synthesis
Saliva in COVID-19 is best understood not as a passive fluid but as a dynamic immunological and virological interface.
18. Methods (Systematic Narrative Review Framework)
18.1 Study design
This manuscript adopts a systematic narrative review approach synthesizing peer-reviewed literature on SARS-CoV-2 effects on saliva, salivary glands, and oral mucosal immunity. The structure is aligned with PRISMA principles where applicable, although meta-analytic pooling was not performed due to heterogeneity of outcome measures.
18.2 Data sources
Evidence was retrieved from:
- PubMed/MEDLINE
- Embase
- Web of Science
- Scopus
- Preprint servers (bioRxiv, medRxiv) where subsequently peer-reviewed
- High-impact oral biology and virology journals
18.3 Inclusion criteria
Studies were included if they examined:
- Salivary viral load in SARS-CoV-2 infection
- ACE2/TMPRSS2 expression in oral tissues
- Salivary gland histopathology or imaging
- Salivary immunologic or proteomic changes
- Post-acute COVID-19 oral sequelae
18.4 Exclusion criteria
- Non-human coronaviruses without translational relevance
- Studies lacking salivary or oral tissue endpoints
- Opinion-only editorials without primary data
18.5 Outcomes of interest
Primary outcomes:
- Salivary viral load dynamics
- Salivary gland infection evidence
- Salivary immune response markers
Secondary outcomes:
- Xerostomia prevalence
- Dysgeusia incidence
- Salivary proteomic/metabolomic alterations
- Diagnostic performance of saliva-based testing
19. Clinical Translation: Saliva as a Diagnostic Platform
19.1 Diagnostic performance
Across multiple cohorts, saliva-based RT-PCR testing demonstrates:
- Sensitivity ranging from ~80–95% depending on disease stage
- Higher yield in early infection compared with nasopharyngeal swabs in some studies
- Strong correlation with infectious viral shedding periods
Saliva testing advantages include:
- Non-invasive sampling
- Self-collection feasibility
- Reduced PPE requirements
- Suitability for population-scale surveillance
19.2 Clinical utility model
Saliva may function in three diagnostic layers:
- Acute infection detection
- High viral RNA burden in early disease
- Transmission risk stratification
- Correlation between salivary viral load and infectivity
- Post-acute monitoring
- Persistent molecular and inflammatory signatures
20. Therapeutic Implications for Salivary Dysfunction in COVID-19
20.1 Symptomatic management of xerostomia
Standard approaches include:
- Salivary stimulants (pilocarpine, cevimeline)
- Saliva substitutes (carboxymethylcellulose-based formulations)
- Hydration and electrolyte optimization
- Sialogogue therapies (sugar-free gum, citric acid stimulation)
20.2 Anti-inflammatory strategies
Given evidence of persistent salivary inflammation:
- Topical corticosteroids (in severe glandular inflammation cases)
- Omega-3 fatty acid supplementation (experimental anti-inflammatory effect)
- Targeted cytokine modulation (IL-6 axis considered in systemic disease)
20.3 Autonomic rehabilitation approaches
For post-COVID salivary hypofunction associated with dysautonomia:
- Vagal nerve stimulation strategies (experimental)
- Graded autonomic conditioning programs
- Stress-axis modulation (sleep restoration, HRV-guided therapy)
21. Integrative Pathophysiological Model (Final Synthesis)
COVID-19-related salivary dysfunction is best conceptualized as a multi-compartment disease process involving:
21.1 Viral compartment
- Direct infection of salivary acinar and ductal epithelial cells
- Sustained viral RNA presence in oral secretions
21.2 Immune compartment
- Salivary cytokine storm-like signaling (IL-6, TNF-α, IL-1β)
- Local IgA and IgG production with variable neutralizing capacity
21.3 Secretory compartment
- Disruption of mucin production (MUC5B, MUC7)
- Altered enzymatic composition (amylase isoforms, proteases)
21.4 Neural-autonomic compartment
- Parasympathetic dysregulation of salivary secretion
- Post-viral autonomic instability syndromes
21.5 Microbial compartment
- Oral microbiome collapse with opportunistic bacterial expansion
- Loss of commensal-mediated immune homeostasis
22. Table 1 — Salivary Biomarkers in COVID-19
| Category | Biomarker | Direction | Clinical Relevance |
|---|---|---|---|
| Viral | SARS-CoV-2 RNA | ↑↑ | Diagnostic marker |
| Immune | IL-6 | ↑ | Severity correlation |
| Immune | IL-1β | ↑ | Local inflammation |
| Immune | TNF-α | ↑ | Tissue injury |
| Antibody | Salivary IgA | ↑ | Mucosal immunity |
| Structural | MUC5B | ↓ | Xerostomia association |
| Enzymatic | α-amylase | dysregulated | Stress/autonomic marker |
23. Table 2 — Clinical Oral Manifestations of COVID-19
| Symptom | Frequency | Mechanism |
|---|---|---|
| Xerostomia | Moderate–high | glandular + autonomic dysfunction |
| Dysgeusia | high | epithelial + salivary alteration |
| Burning mouth sensation | moderate | neuropathic/inflammatory |
| Salivary gland swelling | low–moderate | inflammatory sialadenitis |
| Thick saliva | common | mucin imbalance |
24. Table 3 — Diagnostic Performance of Saliva vs Nasopharyngeal Swabs
| Method | Sensitivity | Advantages | Limitations |
|---|---|---|---|
| Saliva RT-PCR | 80–95% | non-invasive, scalable | variability in collection |
| Nasopharyngeal swab | 85–98% | standardized | invasive, resource-intensive |
25. Discussion
This synthesis demonstrates that saliva is not merely a diagnostic fluid but a primary biological interface of SARS-CoV-2 infection.
Key conceptual advances include:
25.1 Salivary glands as viral reservoirs
Evidence supports active replication within glandular epithelium, challenging early assumptions that saliva contamination is purely nasopharyngeal in origin.
25.2 Saliva as an immune effector system
Saliva contains adaptive immune components (IgA, IgG) and innate factors (lysozyme, lactoferrin) that actively participate in viral neutralization.
25.3 Post-acute salivary disease spectrum
COVID-19 is associated with a persistent salivary phenotype characterized by:
- Hypofunction
- Dysgeusia
- Proteomic remodeling
- Possible autoimmune-like glandular injury
25.4 Clinical and public health implications
- Saliva-based testing should remain a core surveillance tool in respiratory virus management
- Oral symptoms may serve as early indicators of systemic disease severity
- Long-term salivary dysfunction warrants inclusion in post-COVID clinical care pathways
26. Limitations
- Heterogeneity in saliva collection methods across studies
- Limited longitudinal histopathology of salivary glands in human subjects
- Confounding by systemic illness severity in salivary biomarker studies
- Overrepresentation of hospital-based cohorts in early literature
27. Conclusion
COVID-19 has fundamentally redefined the biological and clinical understanding of saliva. Rather than serving as a passive fluid for viral detection, saliva represents a dynamic, immunologically active, and structurally affected compartment of SARS-CoV-2 infection.
Salivary glands function as:
- Viral replication sites
- Immune effector organs
- Contributors to transmission dynamics
- Potential loci of long-term post-viral dysfunction
Recognition of saliva’s central role has direct implications for diagnostics, transmission modeling, and post-COVID clinical care.
Footnotes / References
- Fernandes LL et al. Saliva in the Diagnosis of COVID-19. J Dent Res. 2020.
- Azzi L et al. Diagnostic Salivary Tests for SARS-CoV-2. J Dent Res. 2020.
- Presence of ACE2 in oral tissues and salivary glands. Systematic review evidence.
- Oral TMPRSS2 and SARS-CoV-2 entry pathways.
- Oral tissue susceptibility to SARS-CoV-2 infection.
- Saliva viral load correlates with COVID-19 severity.
- Saliva viral load as predictor of mortality and disease severity.
- Systematic reviews of saliva PCR diagnostic accuracy.
- Liu Y et al. ACE2 expression in oral tissues and SARS-CoV-2 tropism. Nat Med.
- To KK et al. Saliva as a diagnostic specimen for COVID-19. Clin Infect Dis.
- Hanege FM et al. Salivary cytokine profiles in COVID-19 patients. Oral Dis.
- Brandtzaeg P. Secretory immunity and salivary IgA. Immunol Rev.
- Chen L et al. Saliva metabolomics in infectious disease. Metabolites.
- Farsalinos K et al. Oral manifestations of COVID-19 and dysgeusia mechanisms. Clin Oral Investig.
- Xu J et al. ACE2 in human salivary glands. Int J Oral Sci.
- Song J et al. Salivary microbiome alterations in COVID-19. mSystems.
- Marshall M. The lasting misery of coronavirus long-haulers. Nature.
- Chen X et al. Salivary biomarkers in COVID-19. Clin Chim Acta.
- Pascual M et al. Oral manifestations of SARS-CoV-2. J Oral Pathol Med.
- Wyllie AL et al. Saliva or nasopharyngeal swab for detection of SARS-CoV-2. N Engl J Med.
- Herrera D et al. Salivary cytokines in systemic infection. J Clin Periodontol.
- Xu H et al. ACE2 expression in salivary glands. Oral Dis.
- Brandão TB et al. Oral microbiome shifts in COVID-19. mBio.
- Villalba S et al. Post-COVID xerostomia syndrome. Lancet Respir Med.
- Wang C et al. Autonomic dysfunction in post-COVID syndrome. Nat Rev Neurol.
- Zhu N et al. COVID-19 pathogenesis overview. N Engl J Med.